Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Outcomes for 24 patients with metastatic MITF family translocation renal cell carcinoma treated with an immune checkpoint inhibitor (ICI)

From: Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

Patient number Sex Age at diagnosis, years Translocation type TNM at diagnosis FISH analysis Karnofsky score Heng score (IDMC criteria) First treatment line Response to 1st line PFS (mo) Immunotherapy treatment ICI line Response to ICI Duration of response (mo) Deseased Survival (mo)
1 F 25 TFE B T3N2M1 available 100 2 Sunitinib PD 2 Ipilimumab 4 PR 9.0 no 40
2 F 3 TFE 3+ TxN0M0 available 100 1 Sunitinib PD 1 Ipilimumab 5 PD 2.5 yes 23.5
3 F 13.7 TFE 3+ T2N + M+ available 60 3 Pazopanib PR 4 Ipilimumab 3 PD 2,0 yes 20.7
4 F 10 TFE 3+ TxNxM0 available < 80 1 Everolimus PD 4.4 Atezolizumab 2 PD 0.8 no 19
5 F 35.5 TFE 3+ T2bN1Mx available 100 4 Sunitinib PD 4.4 Nivolumab 5 PD 1.0 yes 24.5
6 M 22 TFE 3+ pT1bNxM0 available 100 1 Sunitinib PD 1 Nivolumab 2 PR 8.3 no 17
7 F 26.7 TFE 3+ pT1bNxMxR1 available 100 0 Sunitinib PD 4 Nivolumab 3 PD 2.4 no 25
8 M 60.7 TFE B pT3cN0M1R1 available 100 1 Sunitinib PD 3.1 Nivolumab 3 PD 2.5 yes 19.5
9 F 35 TFE 3+ pT3aN1Mx available 100 1 Sunitinib PD 2.7 Nivolumab 2 PD 1.0 yes 9.6
10 M 41.9 TFE 3+ pT3bN1Mx no 90 1 Pazopanib PD 1.2 Nivolumab 2 PD 1.4 yes 8.5
11 F 35.1 TFE 3+ T3cN0M0 available 90 1 High dose IL-2 PD 0.1 MEDI4736 + Tremelimumab 4 PD 2.4 yes 16.9
12 F 16.1 TFE 3+ T1aN1M1 available 70 2 Sunitinib +nivolumab SD 3.2 Sunitinib +nivolumab 1 PR 3.2 yes 7.6
13 F 79.5 TFE 3+ T3aN0M0 available 60 1 Temsirolimus SD 1.2 Nivolumab 5 PD 1.0 yes 17.3
14 F 54 TFE 3+ T2aN0M1 available 80 2 Pazopanib PR 17.2 Nivolumab 2 SD 15.4 no 84.6
15 F 42.8 TFE 3+ T3N + M+ available 100 1 Sunitinib SD 22 Nivolumab 4 PD 9.0 no 59
16 M 32 TFE B T3bN0M1 available 80 0 Sunitinib PD 1 Nivolumab 2 SD 14 no 25
17 F 29.4 TFE 3+ T4N1M1 available 80 5 Pazopanib SD 3 Nivolumab 2 PD 3 no 4
18 F 26.7 TFE 3+ NA no 90 2 Sunitinib SD 15 pembro +41BB agonist 3 PR 30 yes 60
19 F 49 TFE 3+ pT4pN1pM1 no NA 1 Sunitinib PD 3 Nivolumab 2 SD 8.5 yes 19
20 F 43 TFE 3+ T3bN0M0 available 90 1 Sunitinib PD 1.5 Nivolumab 3 PD 1 yes 8
21 F 63 TFE 3+ pT3aNxMx available 90 1 Sunitinib PD 6 Nivolumab 5 PD 2 yes 24
22 F 48.2 TFE 3+ T3NxM1 available 70 3 Sunitinib PD 3 Nivolumab 2 PD 2 no 5
23 F 45 TFE 3+ pT3aNxM1R1 available 80 1 Sunitinib PD 2 Nivolumab 2 PD 3 yes 9
24 F 24 TFE 3+ pT2bN1 available NA 1 Sorafenib SD 12 Nivolumab 3 PD 4 no 70
  1. PR: partial response; SD: stable disease; PD: progressive disease
Back to article page